Vidaza

multilineage dysplasia, induction chemotherapy, Anemia, Refractory + 11 more

Treatment

4 FDA approvals

20 Active Studies for Vidaza

Treatment for

multilineage dysplasia

What is Vidaza

AzacitidineThe Generic name of this drug

Treatment SummaryAzacytidine is a type of drug used to treat cancer. It works by inhibiting an enzyme called DNA methyltransferase, which helps to prevent the growth of tumors. It also works by blocking the production of RNA, which is essential for cell growth. Azacytidine has been used as an anti-cancer drug for many years.

Vidazais the brand name

image of different drug pills on a surface

Vidaza Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Vidaza

Azacitidine

2004

Approved as Treatment by the FDA

Azacitidine, commonly known as Vidaza, is approved by the FDA for 4 uses like multilineage dysplasia and Leukemia, Myeloid, Acute .

multilineage dysplasia

Leukemia, Myeloid, Acute

Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Effectiveness

How Vidaza Affects PatientsAzacitidine is thought to work against cancer by changing the way DNA is made and by killing abnormal cells in the bone marrow. It does this by affecting the way cells use and make DNA. Azacitidine is most effective when cells are rapidly dividing, as normal cells that aren't dividing don't react to it. Once inside cells, it is changed into other forms which disrupt the way the cell makes RNA and proteins, as well as DNA. Azacitidine is most effective when cells are in the S-phase of the cell cycle.

How Vidaza works in the bodyAzacitidine is a medication that works by preventing the growth of cancer cells. It does this by blocking the activity of DNA methyltransferase, which stops the cells from reproducing. It also has a toxic effect on the cells, causing them to die. Azacitidine is incorporated into DNA and RNA, which disrupts the cells' ability to produce proteins, which leads to their death.

When to interrupt dosage

The measure of Vidaza is contingent upon the determined condition, including induction chemotherapy, 20-30% blasts and Anemia. The measure of dosage shifts as indicated by the strategy of delivery (e.g. Subcutaneous or Tablet - Oral) specified in the chart below.

Condition

Dosage

Administration

Anemia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral

Complete Remission

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Acute Myeloid Leukemia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

multilineage dysplasia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Leukemia, Myeloid, Acute

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Blood Transfusion

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

induction chemotherapy

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Complete Blood Count

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Anemia, Refractory

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Chronic Myelomonocytic Leukemia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Anemia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Malignant Neoplasms

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

neutropenia and/or thrombocytopenia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Anemia

100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg

Warnings

Vidaza has two prohibitions and should not be taken when you are dealing with any of the conditions given in the following table.Vidaza Contraindications

Condition

Risk Level

Notes

Liver Neoplasms

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Azacitidine may interact with Pulse Frequency

There are 20 known major drug interactions with Vidaza.

Common Vidaza Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Azacitidine is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Azacitidine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Azacitidine is combined with Abatacept.

Abetimus

Major

The risk or severity of adverse effects can be increased when Azacitidine is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Azacitidine is combined with Acteoside.

Vidaza Toxicity & Overdose RiskA patient who overdosed on azacitidine reported experiencing diarrhea, nausea, and vomiting. The patient had received a single IV dose of nearly 4 times the recommended starting dose (290 mg/m2).

image of a doctor in a lab doing drug, clinical research

Vidaza Novel Uses: Which Conditions Have a Clinical Trial Featuring Vidaza?

Currently, 367 active studies are examining the potential benefits of Vidaza for treating Chronic Myelomonocytic Leukemia, Blood Transfusion and Multilineage Dysplasia.

Condition

Clinical Trials

Trial Phases

Acute Myeloid Leukemia

265 Actively Recruiting

Phase 2, Phase 3, Phase 1, Phase 4, Not Applicable, Early Phase 1

Complete Remission

0 Actively Recruiting

Chronic Myelomonocytic Leukemia

54 Actively Recruiting

Phase 1, Phase 2, Phase 3, Early Phase 1

Anemia, Refractory

0 Actively Recruiting

Blood Transfusion

0 Actively Recruiting

induction chemotherapy

0 Actively Recruiting

Complete Blood Count

0 Actively Recruiting

Anemia

0 Actively Recruiting

Anemia

0 Actively Recruiting

neutropenia and/or thrombocytopenia

0 Actively Recruiting

Leukemia, Myeloid, Acute

0 Actively Recruiting

Malignant Neoplasms

0 Actively Recruiting

Anemia

0 Actively Recruiting

multilineage dysplasia

0 Actively Recruiting